Silas Inman
Articles
Induction and Maintenance With Ibrutinib Proves Effective for Mantle Cell Lymphoma
January 12, 2023
Article
Adding induction to standard chemoimmunotherapy followed by autologous stem cell transplantation and maintenance ibrutinib was highly effective in patients with mantle cell lymphoma.
Zanubrutinib Outperforms Ibrutinib in Head-to-Head Trial for Relapsed/Refractory CLL/SLL
January 11, 2023
Article
Zanubrutinib demonstrated a superior reduction in the risk of progression or death for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma compared with ibrutinib.
Pirtobrutinib Displays High Response Rate in Pretreated Waldenström Macroglobulinemia
December 27, 2022
Article
Heavily pretreated patients with Waldenström macroglobulinemia demonstrated encouraging responses with pirtobrutinib, a non-covalent BTK inhibitor.
Second-Line Liso-Cel Continues to Improve Event-Free Survival in Large B-Cell Lymphoma
December 25, 2022
Article
In the second line setting, lisocabtagene maraleucel (liso-cel; Breyanzi) significantly reduced the risk of an event for patients with high-risk relapsed/refractory large B-cell lymphoma, compared with standard-of-care chemoimmunotherapy induction.
Upfront Dostarlimab/Chemotherapy Yields Better Risk Reduction Than Pembrolizumab/Chemotherapy in NSCLC
December 14, 2022
Article
Patients with metastatic non-squamous non–small cell lung cancer who received frontline dostarlimab (Jemperli) plus chemotherapy experienced a risk of disease progression or death that was 30% greater than that experienced with pembrolizumab (Keytruda).
Phase 3 Findings Showcase PFS Benefit with Sotorasib for Patients With KRAS G12C+ NSCLC
September 24, 2022
Article
Sotorasib doubled the progression-free survival rate in patients with KRAS G12C–mutated non–small cell lung cancer.
TIL Therapy Outperforms Ipilimumab in Extending Progression-Free Survival in Unresectable Melanoma
September 20, 2022
Article
At a median follow-up of 33.0 months, the median progression-free survival with tumor-infiltrating lymphocyte therapy was 7.2 months vs 3.1 months with ipilimumab.
5-Year Follow-Up Shows Neoadjuvant T-VEC Benefit in Patients with Resectable Melanoma
September 13, 2022
Article
The relapse-free survival rate was 22.3% among patients with resectable stage IIIB to IV M1a melanoma who received neoadjuvant talimogene laherparepvec versus 15.2% among those who received surgery alone.
Trastuzumab Deruxtecan Is Effective Option for HER2-Low MBC
June 06, 2022
Article
Findings from DESTINY-Breast04 (NCT03734029) support the use of trastuzumab deruxtecan in patients with hormone receptor–positive, HER2-low metastatic breast cancer.
Trastuzumab Deruxtecan Demonstrates Favorable Safety Profile in HER+ Metastatic Breast Cancer
June 05, 2022
Article
Updated safety findings from DESTINY-Breast03 showed that treatment with trastuzumab deruxtecan was safe and tolerable for patients with HER2-positive metastatic breast cancer.